Ciphergen Biosystems(CIPH): Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH):

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (235)	7/10/2004 8:09:27 PM
From: tuck	Read Replies (1) of 510

>>Power3 to Begin Clinical Evaluation of Proteomics-Based Breast Cancer Test By a GenomeWeb staff reporter NEW YORK, July 8 (GenomeWeb News) - Power3 Medical Products announced today that clinical evaluation of its proteomics-based early-detection breast cancer test will commence sometime this summer. According to an outside spokesperson for Power3, the company will begin clinical testing at three undisclosed US sites, and that it would likely be able to announce the exact timing of the trials in a few weeks. The test uses proteomics techniques such as electrophoresis image analysis and automated mass spectrometry to analyze nipple aspirate, or breast ductal fluid for specific groups of breast cancer proteins. The fluid is collected via a non-invasive modified breast pump procedure. Power3 said that the test has the potential to detect breast cancer years earlier than current methods. The company also said it has completed proof-of-concept studies and secured the intellectual property for the test. In May, Power3 acquired proteomics start-up ProteEx, which had been developing the test in collaboration with the M.D. Anderson Cancer Center.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next